Posts

Showing posts with the label Mastocytosis market outlook

Mastocytosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Mastocytosis is a disorder resulting from the increased proliferation of mast cells involved in the immune system. The disease can manifest cutaneously (involving the skin) and systemically (affecting multiple body systems). The skin is the most commonly affected area and can present with various cutaneous manifestations, including urticaria pigmentosa, diffuse cutaneous mastocytosis, mastocytoma, and telangiectasia macularis eruptiva perstans. Clinical symptoms include flushing, itching, abdominal pain, diarrhea, hypotension, fainting, and musculoskeletal pain caused by the release and infiltration of mast cell mediators into various organs such as the skin, gastrointestinal tract, liver, spleen, lymph nodes, and bone marrow. Mastocytosis has been classified into seven categories according to the World Health Organization (WHO) consensus: cutaneous mastocytosis, indolent systemic mastocytosis, systemic mastocytosis with associated clonal hematological non–mast cell lineage dis...

Mastocytosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
 Mastocytosis is a disorder resulting from the increased proliferation of mast cells involved in the immune system. The disease can manifest cutaneously (involving the skin) and systemically (affecting multiple body systems). The skin is the most commonly affected area and can present with various cutaneous manifestations, including urticaria pigmentosa, diffuse cutaneous mastocytosis, mastocytoma, and telangiectasia macularis eruptiva perstans. Clinical symptoms include flushing, itching, abdominal pain, diarrhea, hypotension, fainting, and musculoskeletal pain, caused by the release and infiltration of mast cell mediators into various organs such as the skin, gastrointestinal tract, liver, spleen, lymph nodes, and bone marrow. It has been classified into seven categories according to the World Health Organization (WHO) consensus: cutaneous mastocytosis, indolent systemic mastocytosis, systemic mastocytosis with associated clonal hematological non–mast cell lineage disease, aggres...